Trial Profile
Post-marketing Registry to Assess Usage Information, Safety and Effectiveness of Deltyba® Tablets in Korean Patients With Pulmonary Multi-drug Resistant Tuberculosis (MDR-TB)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Sep 2021
Price :
$35
*
At a glance
- Drugs Delamanid (Primary)
- Indications Tuberculosis
- Focus Therapeutic Use
- Sponsors Korea Otsuka Pharmaceutical
- 16 Sep 2021 Status changed from active, no longer recruiting to completed.
- 15 Sep 2020 Planned primary completion date changed from 1 Jun 2020 to 1 Dec 2021.
- 23 Feb 2020 Planned primary completion date changed from 1 Dec 2019 to 1 Jun 2020.